Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.43 |
| ▸ | MMP9 | P14780 | 5/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.40 |
| ▸ | ITGAV | P06756 | 4/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27608126 | 1.00 | MMP2 (0.43) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL4955666 | 0.95 | MMP2 (0.42) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL26463144 | 0.95 | SYK (0.42) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL8313513 | 0.95 | SYK (0.42) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL4654777 | 0.90 | MAPT (0.40) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL14271433 | 0.90 | MAPT (0.40) | MMP2MMP9SYKMMP1MMP3 | |
| SCHEMBL4960020 | 0.87 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL19809645 | 0.87 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6891309 | 0.85 | MMP2 (0.41) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL15911824 | 0.85 | KLK5 (0.43) | SYKITGB3ITGA2BKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060217292-A1 | Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2006-09-28 | — | — | US | disclosed |
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-07-14 | — | — | US | disclosed |
| CN-1582166-A | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | CN | disclosed |
| US-6689337-B2 | TARGETING MOIETY OF A QUINOLONE NONPEPTIDE BOUND TO A CHELATOR AND ALSO BINDS TO A RECEPTOR THAT IS UPREGULATED DURING ANGIOGENESIS; IMAGING COMPOUNDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6683163-B2 | MONITORING ANGIOGENESIS FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | MMP2 2824/4885MMP9 2851/4885SYK 1419/4885 |
| US-20060217292-A1 | Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals | TEK, KDR, EDNRA | MMP2 2198/4885MMP9 2354/4885SYK 3268/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MMP2 2243/4885MMP9 2451/4885SYK 1455/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MMP2 2373/4885MMP9 2630/4885SYK 1207/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MMP2 2243/4885MMP9 2451/4885SYK 1455/4885 |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MMP2 2529/4885MMP9 2180/4885SYK 1156/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | MMP2 2373/4885MMP9 2630/4885SYK 1207/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | MMP2 2373/4885MMP9 2630/4885SYK 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.